Generic drugs approved in 2022 saved patients nearly $19bn in their first year on the market, thanks in large part to follow-ons of Sumitomo Dainippon Pharma’s psychiatric drug Latuda (lurasidone hydrochloride).
Latuda, Other Generics Cleared In 2022 Helped Generate Nearly $19bn In Savings, US FDA Says
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.
More from Generics
More from Market Access
• By
About 3,500 full-time FDA employees are expected to be laid off as part of a restructuring of the Health and Human Services Department and experts questioned whether the cuts could be implemented without harming FDA’s core mission.
• By
A German ordinance implementing the EU Health Technology Assessment Regulation offers little clarity on how far joint clinical assessment reports should be considered by national authorities.
• By
A Republican think tank suggested variations of the Most Favored Nation and international reference policies in Medicare and Medicaid, as well as tariffs and other trade levers to rebalance drug pricing disparities between US countries and abroad.